Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial highlights new evidence on the role of Lp(a) in cardiovascular disease and aortic stenosis, alongside updates in peri-operative management and pharmacogenetics-guided therapy.
With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article. For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Issue contains the ‘2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)’.1 As many years have passed and new evidence has become available since the publication of the 2014 European Society of Cardiology/European Society of Anaethesiology Guidelines on non-cardiac surgery (NCS), the two societies have decided to revise the Guidelines. These new Guidelines are based on the 2014 edition, but all sections have been revised or rewritten, and several new sections have been added. Some of the old recommendations are unchanged or have been revised, and new recommendations have been added. They are intended for physicians, health care workers, and collaborators involved in the pre-operative, operative, and post-operative care of patients undergoing NCS. The objective is to endorse a standardized and evidence-based approach to peri-operative cardiovascular management. The Guidelines recommend a stepwise evaluation of the patient, which integrates clinical risk factors and test results with the estimated stress of the planned surgical procedure and the risks involved with the discontinuation of drugs. This results in an individualized risk assessment to optimize the patient's peri-operative condition. It is important that patients’ values and preferences with respect to the benefits and risks of surgery are taken into consideration, and that patients are involved in the decisions. The issue continues with a focus on dyslipidaemias. We are witnessing a surge of interest in residual lipidic risk unrelated to low-density lipoprotein (LDL)-cholesterol.2-10 In a Special Article entitled ‘Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement’, Florian Kronenberg, from the University of Innsbruck in Austria, and colleagues indicate that their 2022 consensus statement updates evidence for the role of lipoprotein(a) (Lpa) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treating elevated Lp(a) levels, and considers its inclusion in global risk estimation.11 Epidemiological and genetic studies involving hundreds of thousands of individuals strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes in different ethnicities; elevated Lp(a) is a risk factor even at very low levels of low-density lipoprotein cholesterol. High Lp(a) is associated with both microcalcification and macrocalcification of the aortic valve. Current findings do not support Lp(a) as a risk factor for venous thrombotic events and impaired fibrinolysis. Very low Lp(a) levels may associate with increased risk of diabetes mellitus, meriting further study. Lp(a) has pro-inflammatory and pro-atherosclerotic properties, which may partly relate to the oxidized phospholipids carried by Lp(a). This panel recommends testing Lp(a) concentration at least once in adults; cascade testing has potential value in familial hypercholesterolaemia, or with family or personal history of (very) high Lp(a) levels or premature ASCVD. Without specific Lp(a)-lowering therapies, early intensive risk factor management is recommended, targeted according to global cardiovascular risk and Lp(a) level. Lipoprotein apheresis is an option for very high Lp(a) with progressive cardiovascular disease despite optimal management of risk factors. In conclusion, this statement reinforces evidence for Lp(a) as a causal risk factor for cardiovascular outcomes. Trials of specific Lp(a)-lowering treatments are critical to confirm clinical benefit for cardiovascular disease and aortic valve stenosis. Dalcetrapib in patients with AA genotype at variant rs1967309 in the ADCY9 gene. CI, confidence interval; CV, cardiovascular; HR, hazard ratio.12 Cholesteryl ester transfer protein (CETP) plays a pivotal role in lipoprotein metabolism by facilitating the transfer of esterified cholesterol from high-density lipoprotein (HDL) to triglyceride-rich remnant lipoproteins (TRLs) and LDL in exchange for triglycerides. In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib, a CETP inhibitor, on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. In a Fast Track Clinical Research article entitled ‘Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial’, Jean Claude Tardif, from the Université de Montréal in Canada, and colleagues indicate that the dal-GenE study was conducted to test this pharmacogenetic hypothesis.12 dal-GenE was a double-blind trial in patients with an acute coronary syndrome within 1–3 months and the AA genotype at variant rs1967309 in the ADCY9 gene. A total of 6147 patients were randomly assigned to receive dalcetrapib 600 mg or placebo daily. The primary endpoint was the time from randomization to first occurrence of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. After a median follow-up of 39.9 months, the primary endpoint occurred in 9.5% of patients in the dalcetrapib group and 10.6% of patients in the placebo group [hazard ratio (HR) 0.88; P = 0.12] (Figure 1). In a pre-specified on-treatment sensitivity analysis, the primary endpoint event rate was significantly lower in the dalcetrapib group than in the placebo group (HR 0.83). The authors conclude that dalcetrapib does not significantly reduce the risk of occurrence of the primary endpoint of ischaemic cardiovascular events and that a new trial would be needed to test the pharmacogenetic hypothesis that dalcetrapib improves the prognosis of patients with the AA genotype. The contribution is accompanied by an Editorial by Anne Tybjærg-Hansen, Liv Tybjærg Nordestgaard, and Mette Christoffersen from the Copenhagen University Hospital in Denmark.13 They note that the authors should be commended for screening >45 000 patients to finally randomize about 6000 patients with the ADCY9 AA genotype to dalcetrapib or placebo. The dal-GeneE trial was expected to provide a definite answer as to whether dalcetrapib would be protective in the individuals with the AA genotype in the population; however, the results are inconclusive. This question can only be definitively answered in a much larger study with an a priori expected risk reduction which is less than the 22% expected in the present study. Although none of the randomized controlled trials (RCTs) showed associations with age-related macular degeneration (AMD), there were modest signals for AMD in the treatment arm vs. placebo in REVEAL4 and in dal-GenE trials, and a similar trend in the ILLUMINATE trial for ‘serious eye events’, despite the relatively short duration of these trials. CETP inhibitors may not be able to cross the intact Bruch's membrane and gain access to the eye; however, AMD is a late-onset disease and in these elderly individuals Bruch's membrane may not be intact. Therefore, any future RCT of CETP inhibitors should be powered to include long-term data in a sufficient number of elderly individuals to exclude that CETP inhibition causes AMD. In the population-based Rotterdam Study, lipoprotein(a) [Lp(a)] was associated with aortic valve calcification (AVC) onset in multivariable analysis adjusted for age, sex, body mass index, smoking, dyslipidaemia, hypertension, and creatinine. In contrast, progression of AVC was only associated with baseline AVC score, implying that disease progression may take place independently of initiating risk factors. AVC, aortic valve calcification; Lp(a), lipoprotein(a).14 Lp(a) is a potential causal factor in the pathogenesis of aortic valve disease. However, the relationship of Lp(a) with new onset and progression of aortic valve calcium (AVC) has not been studied. In a Clinical Research article entitled ‘Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification’, Yannick Kaiser, from the University Medical Center Rotterdam in The Netherlands, and colleagues assessed whether high serum levels of Lp(a) are associated with AVC incidence and progression.14 A total of 922 individuals from the population-based Rotterdam Study, whose Lp(a) measurements were available, underwent non-enhanced cardiac computed tomography imaging at baseline and after a median follow-up of 14.0 years. New-onset AVC was defined as an AVC score >0 on the follow-up scan in the absence of AVC on the first scan. Progression was defined as the absolute difference in AVC score between the baseline and follow-up scan. Logistic and linear regression analyses were performed to evaluate the relationship of Lp(a) with baseline, new onset, and progression of AVC. All analyses were corrected for age, sex, body mass index, smoking, hypertension, dyslipidaemia, and creatinine. Of the 702 individuals without AVC at baseline, 59% developed new-onset AVC on the follow-up scan. In those with baseline AVC, median annual progression was 13.5 Agatston units. Lp(a) concentration was independently associated with baseline AVC [odds ratio (OR) 1.43 for each 50 mg/dL higher Lp(a)] and new-onset AVC [OR 1.3 for each 50 mg/dL higher Lp(a)], but not with AVC progression (Figure 2). Only baseline AVC score was significantly associated with AVC progression (P <.001). The authors conclude that in the population-based Rotterdam Study, Lp(a) is robustly associated with baseline and new-onset AVC but not with AVC progression, suggesting that Lp(a)-lowering interventions may be most effective in pre-calcific stages of aortic valve disease This manuscript is accompanied by an Editorial by Florian Kronenberg, from the University of Innsbruck in Austria.15 Kronenberg highlights that these findings, together with earlier studies, are an important basis for the planning of interventional studies that might help to avoid a similar experience to that seen in the LDL-cholesterol-lowering trials that targeted the endpoint aortic valve stenosis. Selecting patients without first aortic valve calcifications, deciding on high Lp(a) concentrations (e.g. above the 90th percentile) as an inclusion criterion, a sufficiently long observation period, and probably ‘intermediate’ endpoints on the way to valvular replacement therapy, will be important key points for the planning of new studies in this setting. Cardiovascular disease and brain disorders are frequently linked and are among the leading causes limiting patient's quality of life.16-19 In a State of the Art Review article entitled ‘Heart–brain interactions in cardiac and brain diseases: why sex matters’ Alexia Rossi from the University Hospital Zurich in Switzerland, and colleagues note that the intimate crosstalk between the heart and the brain, results from a complex network of several physiological and neurohumoral circuits.20 From a pathophysiological perspective, both organs share common risk factors, such as hypertension, diabetes, smoking or dyslipidaemia, and are similarly affected by systemic inflammation, atherosclerosis, and dysfunction of the neuroendocrine system. In addition, there is an increasing awareness that physiological interactions between the two organs play important roles in potentiating disease and that sex- and gender-related differences modify those interactions between the heart and the brain over the entire lifespan. The present review summarizes contemporary evidence of the effect of sex on heart–brain interactions and how these influence pathogenesis, clinical manifestation, and treatment responses of specific heart and brain diseases. The editors hope that this issue of the European Heart Journal will find the interest of its readers. Dr. Crea reports speaker fees from Amgen, Astra Zeneca, Servier, BMS, other from GlyCardial Diagnostics, outside the submitted work.
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: